|
(ÁÖ)ÇÏÀ̼¾½º¹ÙÀÌ¿À |
ÀÓ»ó½ÃÇè °ü¸®ÀÚ(CRA) °æ·ÂÁ÷ ä¿ë
°æ±â °úõ½Ã | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
2³â¡è |
ä¿ë½Ã |
06.11 |
|
|
(ÁÖ)ÇÏÀ̼¾½º¹ÙÀÌ¿À |
»ç¾÷°³¹ß °æ·ÂÁ÷ ä¿ë
°æ±â °úõ½Ã | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
4³â¡è |
ä¿ë½Ã |
06.11 |
|
|
Äܸ޵åÄÚ¸®¾Æ(À¯) |
[¹Ì±¹°è ÀÇ·áÀåºñ] Product Specialist
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
¸¶ÄÉÆÃ/±âȹ/±³À° |
3³â¡è |
ä¿ë½Ã |
06.09 |
|
|
Äܸ޵åÄÚ¸®¾Æ(À¯) |
[¹Ì±¹°è ÀÇ·áÀåºñ] Sales Representative
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
Á¦¾à¿µ¾÷/ÀÇ·á±â¿µ¾÷ |
½ÅÀÔ |
ä¿ë½Ã |
06.09 |
|
|
Çູ³ª·¡ ÁÖ½Äȸ»ç |
¿µ¾÷Á÷
¼¿ï ÀüÁö¿ª | ´ëÇÐ(2~3³â) Á¹¾÷ |
˂ȍ |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.09 |
|
|
ÁÖ½Äȸ»ç ÀνºÆÃÅͽº |
[Sexual Healthcare EVE] RA ä¿ë(¾à»ç ¿ì´ë)
¼¿ï ÀüÁö¿ª | Çз¹«°ü |
°³¹ß/RA/´ë°ü |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.09 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] Pharmacovigilance Team ÀÎÅÏ»ç¿ø ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
PL/PV/PMS/MD |
°æ·Â¹«°ü |
ä¿ë½Ã |
06.07 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Feasibility - Site ID Specialist
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
SSU |
2³â¡è |
ä¿ë½Ã |
06.03 |
|
|
PSI CRO Korea |
[PSI CRO Korea] CRA I/II
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
1³â¡è |
ä¿ë½Ã |
06.01 |
|
|
PSI CRO Korea |
[PSI CRO Korea] Senior CRA I/II (Lead Monitor Role)
¼¿ï ¼ÛÆı¸ | Çз¹«°ü |
CRA/ÀÓ»óPM/CRM |
5³â¡è |
ä¿ë½Ã |
06.01 |
|
|
µ§Ã÷ÇöóÀ̽÷γª |
[¿Ü±¹°è ÀÇ·á±â±â] RA/QA Specialist
¼¿ï ¼ÛÆı¸ | ´ëÇÐ(4³â) Á¹¾÷ |
°³¹ß/RA/´ë°ü |
1³â¡è |
ä¿ë½Ã |
05.31 |
|
|
ÇÇÇǾ¾ÄÚ¸®¾Æ(ÁÖ) |
[PPC Korea] BD Assistant ä¿ë
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
°æ·Â¹«°ü |
ä¿ë½Ã |
05.27 |
|
|
PPD Korea |
[PPD] ä¿ë°ø°í - Home-Based + JOINING BONUS - Sr CAS Opp
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
SSU |
8³â¡è |
ä¿ë½Ã |
03.03 |
|
|
PPD Korea |
[PPD] ä¿ë°ø°í - Principal Regulatory Affairs Specialist
¼¿ï °³²±¸ | ´ëÇÐ(4³â) Á¹¾÷ |
ÀÓ»ó BD/RA/QA |
8³â¡è |
ä¿ë½Ã |
03.03 |
|
|
(ÁÖ)Á¦´Ï¾Æ |
ºñÀÓ»ó CRO µ¶¼º ½ÃÇè ¹× ¾àÈ¿ Æò°¡ ´ã´çÀÚ (½ÅÀÔ)
°æ±â ¼º³²½Ã Áß¿ø±¸ | ´ëÇÐ(2~3³â) ÀçÇÐ |
¿¬±¸/¿¬±¸±âȹ |
½ÅÀÔ |
ä¿ë½Ã |
05.20 |
|